SERPING1 and hereditary angioedema: Newer disease-specific options for HAE prophylaxis include plasma-derived C1-INH(IV) (Cinryze®, Shire ViroPharma, Lexington, MA), FDA-approved in 2008, a SC formulation of C1-INH (C1-INH[SC]; HAEGARDA®, CSL Behring, Marburg, Germany) approved by the FDA in June 2017, and a SC monoclonal antibody (lanadelumab; TAKHZYROTM, Shire, Lexington, MA) FDA-approved in August, 2018.